1. Dal Negra, R., Turco, P., Pomari, C., and Trevisan, F., Calcitonin nasal spray in patienmts with chronic asthma: a double-blind crossover study vs placebo, Int. J. Clin. Pharmacol. Ther. Toxicol., 29:144-146,1991.
2. Jain NK. Controlled and novel drug delivery.2nd ed. New Delhi: CBS Publisher and distributer;2002.
3. Aungst, B.J., Rogers, N.J., and Shefter, E., Comparison of nasal, rectal, buccal, sublingual and intramuscular insulin efficacy and the effects of a bile salt absorption promoter, The J. Pharmacol. Exp. Ther., 244:23-27, 1988.
4. Aungst, B.J. and Rogers, N.J., Site dependence of absorption-promoting actions of Laureth-9, Na salicylate, Na2EDTA, and Aprotinin on rectal, nasal, and buccal insulin delivery, Pharm. Res., 5:305-308,1988.
5. Lee, W.E., Permeation enhancers for the nasal delivery of protein and peptide therapeutics, Bio Pharm, 3:22-25, 1990.
6. Tengamnuay, P. and Mitra, A.K., Bile salt-fatty acid mixed micelles as nasal absorption promoters of peptides. I. Effects of ionic strength. adjuvant composition, and lipid structure on the nasal absorption of [D- Arg2]Kyotorphin, Pharm. Res., 7:127-133, 1990.
7. Shao, Z. and Mitra, A.K., Nasal membrane and intracellular protein and enzyme release by bile salts and bile salt-fatty acid mixed micelles: correlation with facilitated drug transport, Pharm. Res., 9:1992,1992.
8. Shao, Z. and Mitra, A.K., Bile salt fatty acid mixed micelles as nasal absorption promoters. III. Effects on nasal transport and enzymatic degradation of acyclovir prodrugs, Pharm. Res., 11:243-250,1994.
9. Soyani, A.P. and Chien, Y.W., Systemic delivery of peptides and proteins across absorptive mucosae, Crit. Rev. Therap. Drug Carrier Systems, 13:85-184,1996.
10. Adjei, A., Sundberg, D., Miller, J., and Chun, A., Bioavailability of leuprolide acetate following nasal inhalation delivery to rats and healthy humans, Pharm. Res., 9:244-249,1992.
11. Shimamoto, T., Pharmaceutical aspects. Nasal and depot formulations of leuprolide, J. Androl., 8:S14-S16,1987.
12. Dal Negra, R., Turco, P., Pomari, C., and Trevisan, F., Calcitonin nasal spray in patienmts with chronic asthma: a double-blind crossover study vs placebo, Int. J. Clin. Pharmacol. Ther. Toxicol., 29:144-146,1991.
13. Plosker, G.L. and McTavish, D., Intranasal salcatonin (salmon calcitonin). A review of its pharmacological properties and role in the management of postmenopausal osteoporosis, Drugs Aging, 8:378-400, 1996.
14. Reginster, J.Y. and Lecart, M.P., Efficacy and safety of drugs for Paget's disease of bone, Bone, 17:485S-488S,1995.
15. Berlin CM.Alternative routes of drug administration –Advantage and disadvantage (Subject Review). Pediatrics 1997;100(1):143-150.
16. Zhang H, Zhang J, Streisand J. Oral mucosal drug delivery-clinical pharmacokinetics and therapeutics application. ClinPharmacokinet 2002; 41(9):661-80.
17. NHLBI Guideline2007, pp. 11–12.http://en.wikipedia.org/wiki/Asthma# CITERE FNHLBI_ Guideline2007. (Downloaded on01/08/2012).
18. Squier, C.A., The permeability of oral mucosa, Crit. Rev. Oral Biol. Med., 2:13-32,1991.
19. . GINA 2009, p.2
20. Tippets B, Guilbert TW (2009). "Managing Asthma in Children: Part 1: Making the Diagnosis, Assessing Severity". Consultant for Pediatricians 8 (5).http://www.consultantlive.com/asthma/article/10162/1414747.
21. Miyazaki S, Kawasaki N, Nakamura T, Iwatsu M, Hayashi T, Hou WM, Attwood D. Oral mucosal bioadhesive tablets of pectin and HPMC: in vitro and in vivo evaluation. Int J Pharm 2000; 204:127–32.
22. Martin L, Wilson CG, Koosha F, UchegbuIF. Sustained buccal delivery of the hydrophobic drug denbufylline using physically cross-linked palmitoyl glycol chitosan hydrogels. Eur J Pharm Biopharm 2003; 55: 35–45.
23. Nafee NA, Isamail FA, Boraie NA, Mortada LM. Mucoadhesive delivery systems. Formulation and in vitro/in –vivo evaluation of buccal mucoadhesive tablets containing water soluble drugs. Drug DevInd Pharm 2004; 30(9):995-1004.
24. Singh B, Ahuja N. Development of controlled release bucoadhesive hydrophilic matrices of diltiazem hydrochloride: Optimization of bioadhesion, dissolution, and diffusion parameters. Drug DevInd Pharm 2002;28(4):431-42.
25. Martin A, Bustamante P, Chun AHC. Physical Pharmacy. 4th ed. New Delhi: B.I.WaverlyPvt Ltd;1999.
26. Higuchi WI. Diffusion models useful in biopharmaceutics-drug release rate processes. J Pharm Sci 1967; 56 (3):315-24.
II. Fickian and anomalous release from swellable devices. J Control Release. 1987; 5 (1):37-42.